- Home
- PPBT vs RDHL Comparison
PPBT vs RDHL Comparison
Compare PPBT & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- RDHL
- Stock Information
- Founded
- PPBT 2010
- RDHL 2009
- Country
- PPBT Israel
- RDHL Israel
- Employees
- PPBT N/A
- RDHL N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- RDHL Health Care
- Exchange
- PPBT Nasdaq
- RDHL Nasdaq
- Market Cap
- PPBT 6.2M
- RDHL 4.3M
- IPO Year
- PPBT N/A
- RDHL N/A
- Fundamental
- Price
- PPBT $2.40
- RDHL $2.15
- Analyst Decision
- PPBT Strong Buy
- RDHL
- Analyst Count
- PPBT 1
- RDHL 0
- Target Price
- PPBT $33.00
- RDHL N/A
- AVG Volume (30 Days)
- PPBT 20.0K
- RDHL 18.4K
- Earning Date
- PPBT 08-15-2025
- RDHL 08-28-2025
- Dividend Yield
- PPBT N/A
- RDHL N/A
- EPS Growth
- PPBT N/A
- RDHL N/A
- EPS
- PPBT N/A
- RDHL N/A
- Revenue
- PPBT N/A
- RDHL $8,042,999.00
- Revenue This Year
- PPBT N/A
- RDHL $381.91
- Revenue Next Year
- PPBT N/A
- RDHL N/A
- P/E Ratio
- PPBT N/A
- RDHL N/A
- Revenue Growth
- PPBT N/A
- RDHL 23.17
- 52 Week Low
- PPBT $2.00
- RDHL $1.71
- 52 Week High
- PPBT $13.95
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- PPBT 47.27
- RDHL 64.10
- Support Level
- PPBT $2.35
- RDHL $2.00
- Resistance Level
- PPBT $2.58
- RDHL $2.08
- Average True Range (ATR)
- PPBT 0.12
- RDHL 0.09
- MACD
- PPBT 0.01
- RDHL 0.03
- Stochastic Oscillator
- PPBT 43.75
- RDHL 100.00
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.